



Kuva Labs Inc. Announces Termination of Lisata Therapeutics, Inc. Tender Offer

HOUSTON, TX, UNITED STATES, July 24, 2026 /EINPresswire.com/ -- Houston, TX (July 24, 2026) – Kuva Labs Inc. (“Kuva”) today announced that it and its wholly owned subsidiary, Kuva Acquisition Corp. (the “Purchaser”), were not able to complete the financing necessary to fund the previously announced tender offer to acquire all of the outstanding shares of common stock of Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”).

While Kuva sought an extension, the offer expired at one minute after 11:59 p.m., New York City time, on July 20, 2026, without an extension granted. Because the financing has not been obtained, the offer will not be consummated. Kuva remains interested in pursuing a transaction with Lisata.

The Purchaser has instructed Equiniti Trust Company, LLC, the depositary for the offer, to return all shares that were tendered and not withdrawn to the tendering stockholders as of July 24, 2026. No action is required on the part of tendering stockholders.

Contact:

Mark Land
Kuva Labs, Inc
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/929052995>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2026 Newsmatics Inc. All Right Reserved.